BPC-157
Also called Body Protection Compound 157; pentadecapeptide
An experimental 15-amino-acid peptide studied for tissue repair in lab and animal models. Small human reports exist, but they do not establish it as a treatment for injuries, gut disease or recovery.
Overview
What it is
A synthetic peptide linked to a protective compound described in gastric juice. Products sold under the name can differ in salt form and purity.
How it works
In rat tendon cells, it increased cell movement and survival under stress through FAK and paxillin signaling, without increasing cell multiplication. Animal studies report faster healing of gut, tendon, ligament and muscle injuries.
What the research shows
A 2021 chart review of 16 knee-pain patients reported less pain, but had no control group and mixed in thymosin beta-4. A small pilot in women with interstitial cystitis reported improvement after bladder instillation. A two-person IV safety pilot reported no adverse events. A phase 1 oral safety trial was registered (NCT02637284). FDA found the ulcerative colitis data inadequate.
Studied for
- Tendon healingrats, lab
- Knee painsmall retrospective report
- Interstitial cystitissmall pilot
- IV safetytwo people
Safety and regulatory status
Safety and side effects
No dependable side-effect rate exists. FDA's July 2026 briefing described reports of injection-site redness and swelling, shortness of breath requiring emergency care, and pigmentation changes with a mixed product. FDA also flags immune reactions and impurities. Seek urgent care for breathing difficulty after any injection.
Regulatory status
Not FDA approved. On FDA's compounding safety-risk list; reviewed by the advisory committee in July 2026, which is not approval. Prohibited at all times by WADA (S0).
Mixing and dosing reference
Reference information only. Read before using this section.
BPC-157 (20 mg Vial) Dosage Protocol
- Vial
- 20 mg BPC-157
- Add diluent
- 3 mL
- Concentration
- 6.67 mg/mL
- 1 unit (U-100)
- 66.67 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 200–600 mcg once daily (gradual titration).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 6 units (0.06 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 9 units (0.09 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 200 mcg daily; increase by ~200 mcg every 2 weeks as tolerated.
- Target: 400–600 mcg daily by Weeks 5–8+.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Discard used syringes immediately in a sharps container per WHO guidelines.
Important notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.
Protocol source: PeptideDosages.com
Common questions
Does BPC-157 affect the liver or testosterone?
The research cannot establish either.
Is BPC-157 with TB-500 better?
No controlled study shows an advantage.
Does less pain mean the tissue healed?
No. Pain, function and structural repair are different outcomes.
Found in these blends
Related in Performance and Recovery
Sources and further reading (7)
- FDA. BPC-157 bulk drug substances: briefing, July 2026.
- Chang CH, et al. BPC 157 and tendon healing: outgrowth, survival and migration. J Appl Physiol, 2011.
- Lee E, Padgett B. Intra-articular BPC 157 for knee pain. Altern Ther Health Med, 2021.
- Lee E, et al. BPC-157 in interstitial cystitis: pilot. Altern Ther Health Med, 2024.
- Lee E, Burgess K. Safety of IV BPC157 in humans: pilot. Altern Ther Health Med, 2025.
- WADA. 2026 Prohibited List, S0.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: BPC-157 Research Use Only